Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Review

Serum microRNAs as potential noninvasive biomarkers for glioma

Authors: Xin Yu, Zheng Li

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Gliomas are derived from astroglial precursors or astrocytes, accounting for 40 % central nervous system tumors. MicroRNAs (miRNAs) are a class of endogenous, small (19- to 23-nucleotides) non-coding RNAs involved in cancer progression. Recent studies show that circulating miRNAs are associated with the clinicopathological features and prognosis of gliomas. Serum miRNAs may serve as novel biomarkers for gliomas diagnosis. This review explores the possibilities of using serum miRNAs as prognostic, diagnostic markers, and therapeutic targets in gliomas.
Literature
1.
Zadran S, Remacle F, Levine R. Surprisal analysis of glioblastoma multiform (gbm) microRNA dynamics unveils tumor specific phenotype. PLoS One. 2014;9:e108171.CrossRefPubMedPubMedCentral
2.
Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, Varlet P, et al. Improving the time-machine: estimating date of birth of grade ii gliomas. Cell Prolif. 2012;45:76–90.CrossRefPubMed
3.
Badoual M, Gerin C, Deroulers C, Grammaticos B, Llitjos JF, Oppenheim C, et al. Oedema-based model for diffuse low-grade gliomas: application to clinical cases under radiotherapy. Cell Prolif. 2014;47:369–80.CrossRefPubMed
4.
5.
Low SY, Ho YK, Too HP, Yap CT, Ng WH. MicroRNA as potential modulators in chemoresistant high-grade gliomas. J Clin Neurosci. 2014;21:395–400.CrossRefPubMed
6.
Tao T, Wang Y, Luo H, Yao L, Wang L, Wang J, et al. Involvement of fos-mediated mir-181b/mir-21 signalling in the progression of malignant gliomas. Eur J Cancer. 2013;49:3055–63.CrossRefPubMed
7.
Bralten LB, Nouwens S, Kockx C, Erdem L, Hoogenraad CC, Kros JM, et al. Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas. PLoS One. 2011;6:e22000.CrossRefPubMedPubMedCentral
8.
Dong H, Luo L, Hong S, Siu H, Xiao Y, Jin L, et al. Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. BMC Syst Biol. 2010;4:163.CrossRefPubMedPubMedCentral
9.
Novakova J, Slaby O, Vyzula R, Michalek J. MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun. 2009;386:1–5.CrossRefPubMed
10.
Rafiee MR, Malekzadeh Shafaroudi A, Rohban S, Khayatzadeh H, Kalhor HR, Mowla SJ. Enrichment of a rare subpopulation of mir-302-expressing glioma cells by serum deprivation. Cell J. 2015;16:494–505.PubMedPubMedCentral
11.
Wang J, Yi X, Tang H, Han H, Wu M, Zhou F. Direct quantification of microRNA at low picomolar level in sera of glioma patients using a competitive hybridization followed by amplified voltammetric detection. Anal Chem. 2012;84:6400–6.CrossRefPubMedPubMedCentral
12.
Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S, et al. The mir 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through cxcr4 repression and consequent disruption of the shh-gli-nanog network. Cell Death Differ. 2012;19:232–44.CrossRefPubMed
13.
Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol. 2012;38:271–91.CrossRefPubMedPubMedCentral
14.
Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015;48(3):278–83.CrossRefPubMed
15.
Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in ewing’s sarcoma. Cell Prolif. 2015;48:1–6.CrossRefPubMed
16.
17.
Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through rhoc-akt pathway by targeting hoxd10 in intervetebral disc degeneration. PLoS One. 2013;8:e83080.CrossRefPubMedPubMedCentral
18.
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–54.CrossRefPubMed
19.
Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.PubMed
20.
21.
Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, et al. By downregulating tiam1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2015;6:17559–69.
22.
Ge W, Yu DC, Li QG, Chen X, Zhang CY, Ding YT. Expression of serum mir-16, let-7f, and mir-21 in patients with hepatocellular carcinoma and their clinical significances. Clin Lab. 2014;60:427–34.CrossRefPubMed
23.
Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies mir-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 2011;120:183–93.CrossRef
24.
Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum mir-18a: a potential marker for hepatitis b virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012;57:2910–6.CrossRefPubMed
25.
Guo F, Tian J, Lin Y, Jin Y, Wang L, Cui M. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. J Int Med Res. 2013;41:1456–61.CrossRefPubMed
26.
Shi W, Du J, Qi Y, Liang G, Wang T, Li S, et al. Aberrant expression of serum miRNAs in schizophrenia. J Psychiatr Res. 2012;46:198–204.CrossRefPubMed
27.
Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating mir-378 and mir-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55.CrossRefPubMedPubMedCentral
28.
Rotkrua P, Shimada S, Mogushi K, Akiyama Y, Tanaka H, Yuasa Y. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer. 2013;108:932–40.CrossRefPubMedPubMedCentral
29.
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis b virus. PLoS One. 2014;9:e107986.CrossRefPubMedPubMedCentral
30.
Wu C, Cao Y, He Z, He J, Hu C, Duan H, et al. Serum levels of mir-19b and mir-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 2014;232:85–95.CrossRefPubMed
31.
Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: Novel biomarkers for patients with bladder cancer? World J Urol 2014;32:353–8.
32.
Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum mir-21 and mir-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013;34:2175–81.CrossRefPubMed
33.
Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp Neurol. 2012;235:491–6.CrossRefPubMed
34.
Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum micrornas from a genome-wide serum microrna expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013;132:116–27.CrossRefPubMed
35.
Dong L, Li Y, Han C, Wang X, She L, Zhang H. miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. Int J Oncol. 2014;45:746–56.PubMed
36.
Manterola L, Guruceaga E, Gallego Perez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Tejada S, et al. A small noncoding rna signature found in exosomes of gbm patient serum as a diagnostic tool. Neuro-Oncology. 2014;16:520–7.CrossRefPubMedPubMedCentral
37.
Wu J, Li L, Jiang C. Identification and evaluation of serum microRNA-29 family for glioma screening. Mol Neurobiol. 2015;52:1540–6.
38.
Wei X, Chen D, Lv T, Li G, Qu S. Serum microRNA-125b as a potential biomarker for glioma diagnosis. Molecular neurobiology 2014. [Epub ahead of print]
39.
Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 2015;112(Suppl):1241–6.CrossRefPubMedPubMedCentral
40.
Sun J, Liao K, Wu X, Huang J, Zhang S, Lu X. Serum microRNA-128 as a biomarker for diagnosis of glioma. Int J Clin Exp Med. 2015;8:456–63.PubMedPubMedCentral
41.
Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg 2015:1-7. [Epub ahead of print]
42.
Wang J, Zhang KY, Liu SM, Sen S. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 2014;19:1912–38.CrossRefPubMed
43.
Zavesky L, Jandakova E, Turyna R, Langmeierova L, Weinberger V, Minar L, et al. New perspectives in diagnosis of gynaecological cancers: emerging role of circulating microRNAs as novel biomarkers. Neoplasma. 2015;62(4):509–20.CrossRefPubMed
44.
Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41:1897–912.PubMed
Metadata
Title
Serum microRNAs as potential noninvasive biomarkers for glioma
Authors
Xin Yu
Zheng Li
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4515-7

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

RETRACTED ARTICLE: Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer

Original Article

Reversal of efflux of an anticancer drug in human drug-resistant breast cancer cells by inhibition of protein kinase Cα (PKCα) activity

Original Article

Slug silencing inhibited perineural invasion through regulation of EMMPRIN expression in human salivary adenoid cystic carcinoma

Original Article

The role of Kaposi’s sarcoma-associated herpesvirus infection in the proliferation of human bladder cancer cells

Original Article

Gambogic acid enhances the radiosensitivity of human esophageal cancer cells by inducing reactive oxygen species via targeting Akt/mTOR pathway

Original Article

Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits